Metabolic Flux Data from Engineered Erythromycin-Producing Strain

786.61 mg/L of erythromycin was produced by an engineered strain after a key metabolic pathway was disrupted. The dataset likely contains results from 13C labeling experiments and isotopically nonstationary metabolic flux analysis comparing the original S. erythraea E3 strain with the engineered E3-ΔsucC strain. It was produced by Feng Xu at the East China University of Science and Technology.

Use Cases

• Train models to predict metabolic flux changes based on genetic modifications.
• Analyze the relationship between pentose phosphate pathway flux and secondary metabolite yield.
• Compare the efficiency of glyoxylate bypass versus the tricarboxylic acid cycle in engineered strains.

Strengths

• Includes a specific, quantified production improvement (786.61 vs 392.94 mg/L).
• Describes a clear experimental method using 13C labeling and mass spectrometry metabolomics.
• Reports a significant flux change (almost 200% increase in pentose phosphate pathway).

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect the specific experimental bias inherent to a single academic study.

Provenance

Source

East China University of Science and Technology

Collection Method

13C labeling experiments and isotopically nonstationary 13C metabolic flux analysis.